Apyx Medical (APYX) Proxy filing summary

Executive summary

• The 2026 Annual Meeting will be held on August 6, 2026, with five key proposals up for shareholder vote, including director elections, auditor ratification, executive compensation, and a new share incentive plan.

• The Board unanimously recommends voting in favor of all proposals and emphasizes the importance of shareholder participation.

• Proxy materials, including the annual report, are available online, and multiple voting methods are provided for convenience.

Voting matters and shareholder proposals

• Shareholders will vote on electing five directors, ratifying RSM US LLP as auditor, approving executive compensation (say-on-pay), and adopting the 2026 Share Incentive Plan.

• The Board recommends voting “FOR” all proposals and will use best judgment for any other business arising at the meeting.

• Shareholders can submit proposals for the 2027 meeting by February 27, 2027, and must comply with SEC rules for nominations and proposals.

Board of directors and corporate governance

• The Board consists of five members, three of whom are independent under Nasdaq and SEC rules.

• The Board is led by Executive Chairman Stavros Vizirgianakis, with Lawrence J. Waldman serving as Lead Independent Director.

• Four standing committees exist: Audit, Compensation, Governance and Nominating, and Regulatory Compliance, all composed of independent directors.

• Annual board and committee evaluations are conducted, and executive sessions are held regularly.

• Stockholder communications and a Code of Ethics are in place, with annual review and a whistleblower hotline.